$CMPS
COMPASS Pathways plc

2024 Q3 Form 10-Q Financial Statement

#000162828024033853 Filed on August 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.97M $14.25M
YoY Change 45.89% 48.67%
% of Gross Profit
Research & Development $32.93M $29.07M
YoY Change 52.97% 46.68%
% of Gross Profit
Depreciation & Amortization $59.00K $63.00K
YoY Change -67.22% -42.73%
% of Gross Profit
Operating Expenses $47.90M $43.32M
YoY Change 40.61% 47.33%
Operating Profit -$47.90M -$43.32M
YoY Change 40.61% 32.63%
Interest Expense $5.292M $1.521M
YoY Change 390.0% 10.54%
% of Operating Profit
Other Income/Expense, Net $9.567M $5.397M
YoY Change 1201.63% 71.5%
Pretax Income -$38.33M -$37.93M
YoY Change 15.01% 34.77%
Income Tax $173.0K $176.0K
% Of Pretax Income
Net Earnings -$38.50M -$38.10M
YoY Change 15.31% 34.47%
Net Earnings / Revenue
Basic Earnings Per Share -$0.56 -$560.00
Diluted Earnings Per Share -$0.56 -$560.00
COMMON SHARES
Basic Shares Outstanding 68.39M shares 68.38M shares
Diluted Shares Outstanding 68.40M shares 68.37M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $207.0M $228.6M
YoY Change -16.55% 54.23%
Cash & Equivalents $207.0M $228.6M
Short-Term Investments
Other Short-Term Assets $1.779M $2.699M
YoY Change -14.27% -87.92%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $233.7M $265.1M
YoY Change -17.96% 36.93%
LONG-TERM ASSETS
Property, Plant & Equipment $2.745M $3.179M
YoY Change 788.35% -39.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.518M $6.239M
YoY Change 10.89% -40.57%
Total Long-Term Assets $13.68M $13.44M
YoY Change -3.87% -17.21%
TOTAL ASSETS
Total Short-Term Assets $233.7M $265.1M
Total Long-Term Assets $13.68M $13.44M
Total Assets $247.3M $278.5M
YoY Change -17.29% 32.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.233M $8.195M
YoY Change 93.81% 313.47%
Accrued Expenses $15.82M $13.83M
YoY Change 59.82% 37.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.156M
YoY Change
Total Short-Term Liabilities $26.21M $22.03M
YoY Change 70.76% 72.42%
LONG-TERM LIABILITIES
Long-Term Debt $27.64M $29.43M
YoY Change -2.68% 4.66%
Other Long-Term Liabilities $459.0K $799.0K
YoY Change -77.05% -68.53%
Total Long-Term Liabilities $27.64M $30.23M
YoY Change -9.09% -1.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.21M $22.03M
Total Long-Term Liabilities $27.64M $30.23M
Total Liabilities $54.31M $52.26M
YoY Change 18.63% 20.31%
SHAREHOLDERS EQUITY
Retained Earnings -$491.4M -$452.9M
YoY Change 41.57% 44.37%
Common Stock $699.0K $699.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $193.0M $226.3M
YoY Change
Total Liabilities & Shareholders Equity $247.3M $278.5M
YoY Change -17.29% 32.74%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$38.50M -$38.10M
YoY Change 15.31% 34.47%
Depreciation, Depletion And Amortization $59.00K $63.00K
YoY Change -67.22% -42.73%
Cash From Operating Activities -$22.19M -$34.42M
YoY Change 30.12% 38.7%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -53.00K 210.0K
YoY Change -100.05% -99.62%
NET CHANGE
Cash From Operating Activities -22.19M -34.42M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities -53.00K 210.0K
Net Change In Cash -22.24M -34.21M
YoY Change -122.3% -209.99%
FREE CASH FLOW
Cash From Operating Activities -$22.19M -$34.42M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$22.19M -$34.42M
YoY Change 29.96% 38.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
220638000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143381000 usd
CY2024Q2 cmps Research And Development Tax Credit Income Tax Expense Benefit
ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit
-3709000 usd
CY2023Q2 cmps Research And Development Tax Credit Income Tax Expense Benefit
ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit
-2520000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2385000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2411000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
22027000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19604000 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
29434000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
28757000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
799000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1882000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
52260000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
50243000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.008
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.008
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68387469 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
68387469 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68387469 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
61943471 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61943471 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61943471 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
699000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
635000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
695353000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
621645000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16881000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16926000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-452898000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-379610000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
226273000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
225744000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
278533000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
275987000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29069000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19818000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
799000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1882000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
52260000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
50243000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.008
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.008
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68387469 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
68387469 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68387469 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
61943471 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61943471 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
699000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
695353000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
621645000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16881000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-452898000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-379610000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
226273000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
225744000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
278533000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
275987000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29069000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19818000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12846000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
43322000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-43322000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-32664000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2408000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
638000 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1112000 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
0 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
225000 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1376000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
167000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5397000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14253000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
43322000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
32664000 usd
us-gaap Operating Expenses
OperatingExpenses
81895000 usd
us-gaap Operating Expenses
OperatingExpenses
64452000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-43322000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-32664000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-81895000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-64452000 usd
cmps Research And Development Tax Credit Income Tax Expense Benefit
ResearchAndDevelopmentTaxCreditIncomeTaxExpenseBenefit
-6810000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2408000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
638000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
4668000 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1112000 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
0 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
2210000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
0 usd
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
225000 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1376000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-558000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
167000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
295000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5397000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4523000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37925000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28141000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
176000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
194000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-38101000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-28335000 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-560
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-560
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-620
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-620
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68371139 shares
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4523000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9005000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37925000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28141000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72890000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52219000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
176000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
194000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
398000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-38101000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-28335000 usd
us-gaap Net Income Loss
NetIncomeLoss
-73288000 usd
us-gaap Net Income Loss
NetIncomeLoss
-52543000 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-560
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-560
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-620
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-620
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1110
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1190
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1190
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68371139 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68371139 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66296658 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66296658 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44153772 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44153772 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-38101000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-28335000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
81000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
717000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38020000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27618000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1188000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
109000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-578000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24208000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
161644000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26932000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
189000 usd
CY2023Q2 cmps Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Value Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsValueForfeituresAndExpirations
0 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
687000 usd
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68371139 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45565991 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66296658 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66296658 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44153772 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44153772 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-38101000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-28335000 usd
us-gaap Net Income Loss
NetIncomeLoss
-73288000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
81000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
717000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38020000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27618000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73243000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52404000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
181280000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1188000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
109000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4071000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-578000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24208000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
161644000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26932000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
189000 usd
CY2023Q2 cmps Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Value Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsValueForfeituresAndExpirations
0 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
687000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4561000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
717000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-28335000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
166396000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
225744000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
220000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26219000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q1 cmps Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
37258000 usd
CY2024Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
185000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5129000 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-36000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-35187000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
259162000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
210000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4921000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
81000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-38101000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
226273000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4561000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
717000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-28335000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
166396000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
220000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26219000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q1 cmps Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
37258000 usd
CY2024Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
185000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5129000 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-36000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-35187000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
259162000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
210000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4921000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
81000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
226273000 usd
us-gaap Net Income Loss
NetIncomeLoss
-73288000 usd
us-gaap Net Income Loss
NetIncomeLoss
-52543000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
124000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
677000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-46000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-356000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2251000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
10050000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8632000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1102000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1018000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4662000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-437000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
255000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-637000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
7099000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1082000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-955000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2346000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2899000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
195000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1050000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55244000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52536000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-46000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26219000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28120000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
37258000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
124000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
158000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
677000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-46000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-356000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2251000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
10050000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8632000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1102000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1018000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3202000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4662000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-437000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
255000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-637000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
7099000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1082000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-955000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2346000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2899000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
195000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1050000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55244000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52536000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-46000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26219000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28120000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
37258000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
210000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
189000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
185000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
109000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
29585000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
778000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
220000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63722000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
57008000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-99000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
678000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8379000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5104000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229017000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148485000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228628000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148234000 usd
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
389000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
210000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
189000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
185000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
109000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
778000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
220000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63722000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
57008000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-99000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
678000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8379000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5104000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229017000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148485000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228628000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148234000 usd
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
389000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
251000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229017000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148485000 usd
CY2021Q4 cmps Number Of Ordinary Shares Conversion Ratio
NumberOfOrdinarySharesConversionRatio
1
us-gaap Net Income Loss
NetIncomeLoss
-73300000 usd
us-gaap Net Income Loss
NetIncomeLoss
-52500000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-452900000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228600000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div>
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
251000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229017000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148485000 usd
CY2021Q4 cmps Number Of Ordinary Shares Conversion Ratio
NumberOfOrdinarySharesConversionRatio
1
us-gaap Net Income Loss
NetIncomeLoss
-73300000 usd
us-gaap Net Income Loss
NetIncomeLoss
-52500000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-452900000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228600000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div>
CY2024Q2 cmps Research And Development Tax Credit Current
ResearchAndDevelopmentTaxCreditCurrent
19897000 usd
CY2024Q2 cmps Prepaid Expense Research And Development Current
PrepaidExpenseResearchAndDevelopmentCurrent
10301000 usd
CY2023Q4 cmps Prepaid Expense Research And Development Current
PrepaidExpenseResearchAndDevelopmentCurrent
6826000 usd
CY2024Q2 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1183000 usd
CY2023Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1052000 usd
CY2024Q2 us-gaap Prepaid Taxes
PrepaidTaxes
1123000 usd
CY2023Q4 us-gaap Prepaid Taxes
PrepaidTaxes
1123000 usd
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
873000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1885000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2699000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1895000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
36076000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
40658000 usd
CY2024Q2 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
3300000 usd
CY2024Q2 cmps Options Number Of Shares Available For Purchase Percent Of Principal Amount Of Term Loan Advances
OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances
0.025
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000 usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000 usd
CY2024Q2 cmps Long Term Debt End Of Term Charge
LongTermDebtEndOfTermCharge
1425000 usd
CY2023Q4 cmps Long Term Debt End Of Term Charge
LongTermDebtEndOfTermCharge
1425000 usd
CY2024Q2 cmps Long Term Debt Including End Of Term Charge
LongTermDebtIncludingEndOfTermCharge
31425000 usd
CY2023Q4 cmps Long Term Debt Including End Of Term Charge
LongTermDebtIncludingEndOfTermCharge
31425000 usd
CY2023Q4 cmps Research And Development Tax Credit Current
ResearchAndDevelopmentTaxCreditCurrent
27877000 usd
CY2024Q2 cmps Prepaid Expense Research And Development Current
PrepaidExpenseResearchAndDevelopmentCurrent
10301000 usd
CY2023Q4 cmps Prepaid Expense Research And Development Current
PrepaidExpenseResearchAndDevelopmentCurrent
6826000 usd
CY2024Q2 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1183000 usd
CY2023Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1052000 usd
CY2024Q2 us-gaap Prepaid Taxes
PrepaidTaxes
1123000 usd
CY2023Q4 us-gaap Prepaid Taxes
PrepaidTaxes
1123000 usd
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
873000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
2699000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1895000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
36076000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
40658000 usd
CY2024Q2 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
3300000 usd
CY2024Q2 cmps Options Number Of Shares Available For Purchase Percent Of Principal Amount Of Term Loan Advances
OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances
0.025
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000 usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000 usd
CY2024Q2 cmps Long Term Debt End Of Term Charge
LongTermDebtEndOfTermCharge
1425000 usd
CY2023Q4 cmps Long Term Debt End Of Term Charge
LongTermDebtEndOfTermCharge
1425000 usd
CY2024Q2 cmps Long Term Debt Including End Of Term Charge
LongTermDebtIncludingEndOfTermCharge
31425000 usd
CY2023Q4 cmps Long Term Debt Including End Of Term Charge
LongTermDebtIncludingEndOfTermCharge
31425000 usd
CY2024Q2 cmps Debt Instrument Paid In Kind Interest Payable
DebtInstrumentPaidInKindInterestPayable
431000 usd
CY2023Q4 cmps Debt Instrument Paid In Kind Interest Payable
DebtInstrumentPaidInKindInterestPayable
216000 usd
CY2024Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2422000 usd
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2884000 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
29434000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
28757000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6572000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
14166000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
10687000 usd
CY2024Q2 cmps Long Term Debt Including End Of Term Charge
LongTermDebtIncludingEndOfTermCharge
31425000 usd
CY2024Q2 cmps Debt Instrument Paid In Kind Interest Payable
DebtInstrumentPaidInKindInterestPayable
431000 usd
CY2023Q4 cmps Debt Instrument Paid In Kind Interest Payable
DebtInstrumentPaidInKindInterestPayable
216000 usd
CY2024Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2422000 usd
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2884000 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
29434000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
28757000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6572000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
14166000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
10687000 usd
CY2024Q2 cmps Long Term Debt Including End Of Term Charge
LongTermDebtIncludingEndOfTermCharge
31425000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
2200000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
0 usd
CY2021Q4 cmps Number Of Ordinary Shares Conversion Ratio
NumberOfOrdinarySharesConversionRatio
1
CY2023Q3 cmps Number Of Ordinary Shares Conversion Ratio
NumberOfOrdinarySharesConversionRatio
1
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4921000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4561000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10050000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8632000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
2200000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
0 usd
CY2021Q4 cmps Number Of Ordinary Shares Conversion Ratio
NumberOfOrdinarySharesConversionRatio
1
CY2023Q3 cmps Number Of Ordinary Shares Conversion Ratio
NumberOfOrdinarySharesConversionRatio
1
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4921000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4561000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10050000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8632000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21524016 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7470917 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21524016 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7470917 shares
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001628280-24-033853-index-headers.html Edgar Link pending
0001628280-24-033853-index.html Edgar Link pending
0001628280-24-033853.txt Edgar Link pending
0001628280-24-033853-xbrl.zip Edgar Link pending
cmps-20240630.htm Edgar Link pending
cmps-20240630.xsd Edgar Link pending
cmps-q2x24xex311ceo302cert.htm Edgar Link pending
cmps-q2x24xex312cfo302cert.htm Edgar Link pending
cmps-q2x24xex321ceoxcfosec.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
cmps-20240630_cal.xml Edgar Link unprocessable
cmps-20240630_def.xml Edgar Link unprocessable
cmps-20240630_lab.xml Edgar Link unprocessable
cmps-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cmps-20240630_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending